In:
Digestion, S. Karger AG, Vol. 100, No. 4 ( 2019), p. 247-253
Abstract:
〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Leukocyte removal therapy (LRT) is an effective treatment for active ulcerative colitis (UC). The present study was performed to evaluate the relapse-free period after LRT and identify risk factors for relapse. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 In total, 94 patients who underwent first-time LRT for remission of moderate to severe UC from April 2004 to March 2016 were enrolled in the present study. The patients were randomly assigned to one of 2 treatments: leukocytapheresis (LCAP; 〈 i 〉 n 〈 /i 〉 = 43) or granulocyte and monocyte/macrophage adsorptive apheresis (GMA; 〈 i 〉 n 〈 /i 〉 = 51). The 5-year cumulative relapse-free rate and risk factors for relapse were evaluated. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 The therapeutic response rate was 82% for GMA and 70% for LCAP without a statistically significant difference. The 5-year relapse-free rate was 34.7% in the LRT group. The 5-year relapse-free rate in patients aged & #x3e; 40 years was 49.9%, which was significantly higher than that in patients aged ≤40 years (22.9%, 〈 i 〉 p 〈 /i 〉 & #x3c; 0.01). The relapse-free period was longer in the older than younger patients. 〈 b 〉 〈 i 〉 Conclusions: 〈 /i 〉 〈 /b 〉 The relapse-free period after LRT was examined in patients with UC, and 34.7% of patients achieved clinical remission within a 5-year period. The risk factor for early relapse after LRT was younger age.
Type of Medium:
Online Resource
ISSN:
0012-2823
,
1421-9867
Language:
English
Publisher:
S. Karger AG
Publication Date:
2019
detail.hit.zdb_id:
1482218-0
